Overview Dividends

(RGEN) Repligen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7599161095

Protein A Ligands, Chromatography Columns, Filtration Systems, Process Analytics

EPS (Earnings per Share)

EPS (Earnings per Share) of RGEN over the last years for every Quarter: "2020-09": 0.4, "2020-12": 0.52, "2021-03": 0.68, "2021-06": 0.79, "2021-09": 0.78, "2021-12": 0.81, "2022-03": 0.92, "2022-06": 0.91, "2022-09": 0.77, "2022-12": 0.68, "2023-03": 0.64, "2023-06": 0.53, "2023-09": 0.23, "2023-12": 0.33, "2024-03": 0.28, "2024-06": 0.33, "2024-09": -0.0117, "2024-12": 0.44, "2025-03": 0.39, "2025-06": 0.37, "2025-09": 0.46,
EPS CAGR: -13.25%
EPS Trend: -37.2%
Last SUE: 0.37σ
Qual. Beats: 0

Revenue

Revenue of RGEN over the last years for every Quarter: 2020-09: 94.06, 2020-12: 108.648, 2021-03: 142.837, 2021-06: 162.96, 2021-09: 178.216, 2021-12: 186.521, 2022-03: 206.4, 2022-06: 207.633, 2022-09: 200.741, 2022-12: 186.762, 2023-03: 182.66, 2023-06: 159.169, 2023-09: 141.192, 2023-12: 155.743, 2024-03: 151.346, 2024-06: 154.073, 2024-09: 154.871, 2024-12: 167.547, 2025-03: 169.172, 2025-06: 182.366, 2025-09: 188.805,
Revenue CAGR: 0.40%
Revenue Trend: 18.4%
Last SUE: 2.59σ
Qual. Beats: 3
Risk via 10d forecast
Volatility 48.6%
Value at Risk 5%th 72.0%
Relative Tail Risk -10.00%
Reward TTM
Sharpe Ratio 0.48
Alpha 9.66
Character TTM
Hurst Exponent 0.423
Beta 1.434
Beta Downside 1.421
Drawdowns 3y
Max DD 47.75%
Mean DD 24.00%
Median DD 24.07%

Description: RGEN Repligen November 04, 2025

Repligen Corporation (NASDAQ:RGEN) is a life-sciences firm that designs, manufactures, and sells bioprocessing technologies and systems across North America, Europe, and the Asia-Pacific. Its product portfolio includes Protein A affinity ligands, cell-culture growth factors, OPUS pre-packed and small-scale chromatography columns, filtration devices such as XCell ATF and TangenX cassettes, and process-analytics tools under the SoloVPE/FlowVPE brands. Customers span biopharma, diagnostics, academic labs, and contract manufacturing organizations, and the company maintains a partnership with Navigo Proteins GmbH to co-develop new affinity ligands.

Key recent metrics: FY 2023 revenue reached approximately $1.0 billion, with a gross margin near 70% and recurring consumable sales accounting for roughly 55% of total revenue-a sign of stable, repeatable demand. The bioprocessing market is being driven by a surge in biologics pipelines (projected CAGR ≈ 10% through 2028) and the shift toward single-use, high-throughput platforms that favor Repligen’s chromatography and filtration solutions. Additionally, the company’s cash conversion cycle has shortened to under 45 days, reflecting efficient working-capital management.

For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of RGEN’s financial and operational metrics.

RGEN Stock Overview

Market Cap in USD 8,730m
Sub-Industry Life Sciences Tools & Services
IPO / Inception 1990-03-26
Return 12m vs S&P 500 2.03%
Analyst Rating 4.26 of 5

RGEN Dividends

Currently no dividends paid

RGEN Growth Ratios

Metric Value
CAGR 3y -1.82%
CAGR/Max DD Calmar Ratio -0.04
CAGR/Mean DD Pain Ratio -0.08
Current Volume 892.1k
Average Volume 896.2k

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (1.74m TTM) > 0 and > 6% of Revenue (6% = 42.5m TTM)
FCFTA 0.04 (>2.0%) and ΔFCFTA -0.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 136.4% (prev 166.1%; Δ -29.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.04 (>3.0%) and CFO 130.9m > Net Income 1.74m (YES >=105%, WARN >=100%)
Net Debt (-59.9m) to EBITDA (133.8m) ratio: -0.45 <= 3.0 (WARN <= 3.5)
Current Ratio 8.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (56.5m) change vs 12m ago -0.74% (target <= -2.0% for YES)
Gross Margin 45.38% (prev 46.88%; Δ -1.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 24.60% (prev 21.76%; Δ 2.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.59 (EBITDA TTM 133.8m / Interest Expense TTM 44.3m) >= 6 (WARN >= 3)

Altman Z'' 3.27

(A) 0.33 = (Total Current Assets 1.10b - Total Current Liabilities 131.1m) / Total Assets 2.92b
(B) 0.15 = Retained Earnings (Balance) 443.0m / Total Assets 2.92b
(C) 0.01 = EBIT TTM 26.1m / Avg Total Assets 2.88b
(D) 0.52 = Book Value of Equity 439.4m / Total Liabilities 840.6m
Total Rating: 3.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.05

1. Piotroski 2.50pt
2. FCF Yield 1.23%
3. FCF Margin 15.04%
4. Debt/Equity 0.33
5. Debt/Ebitda -0.45
6. ROIC - WACC (= -9.84)%
7. RoE 0.09%
8. Rev. Trend 18.39%
9. EPS Trend -37.21%

What is the price of RGEN shares?

As of November 24, 2025, the stock is trading at USD 162.51 with a total of 892,067 shares traded.
Over the past week, the price has changed by +6.65%, over one month by +3.67%, over three months by +35.82% and over the past year by +14.64%.

Is RGEN a buy, sell or hold?

Repligen has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy RGEN.
  • Strong Buy: 10
  • Buy: 4
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RGEN price?

Issuer Target Up/Down from current
Wallstreet Target Price 187 15.1%
Analysts Target Price 187 15.1%
ValueRay Target Price 175.8 8.1%

RGEN Fundamental Data Overview November 21, 2025

Market Cap USD = 8.73b (8.73b USD * 1.0 USD.USD)
P/E Trailing = 7754.0005
P/E Forward = 81.9672
P/S = 12.3318
P/B = 4.1361
P/EG = 2.59
Beta = 1.128
Revenue TTM = 707.9m USD
EBIT TTM = 26.1m USD
EBITDA TTM = 133.8m USD
Long Term Debt = 537.9m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 688.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.9m USD (from netDebt column, last quarter)
Enterprise Value = 8.67b USD (8.73b + Debt 688.9m - CCE 748.7m)
Interest Coverage Ratio = 0.59 (Ebit TTM 26.1m / Interest Expense TTM 44.3m)
FCF Yield = 1.23% (FCF TTM 106.5m / Enterprise Value 8.67b)
FCF Margin = 15.04% (FCF TTM 106.5m / Revenue TTM 707.9m)
Net Margin = 0.25% (Net Income TTM 1.74m / Revenue TTM 707.9m)
Gross Margin = 45.38% ((Revenue TTM 707.9m - Cost of Revenue TTM 386.6m) / Revenue TTM)
Gross Margin QoQ = 53.24% (prev 49.98%)
Tobins Q-Ratio = 2.97 (Enterprise Value 8.67b / Total Assets 2.92b)
Interest Expense / Debt = 3.98% (Interest Expense 27.4m / Debt 688.9m)
Taxrate = 12.86% (2.20m / 17.1m)
NOPAT = 22.8m (EBIT 26.1m * (1 - 12.86%))
Current Ratio = 8.36 (Total Current Assets 1.10b / Total Current Liabilities 131.1m)
Debt / Equity = 0.33 (Debt 688.9m / totalStockholderEquity, last quarter 2.08b)
Debt / EBITDA = -0.45 (Net Debt -59.9m / EBITDA 133.8m)
Debt / FCF = -0.56 (Net Debt -59.9m / FCF TTM 106.5m)
Total Stockholder Equity = 2.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.06% (Net Income 1.74m / Total Assets 2.92b)
RoE = 0.09% (Net Income TTM 1.74m / Total Stockholder Equity 2.03b)
RoCE = 1.02% (EBIT 26.1m / Capital Employed (Equity 2.03b + L.T.Debt 537.9m))
RoIC = 0.89% (NOPAT 22.8m / Invested Capital 2.56b)
WACC = 10.73% (E(8.73b)/V(9.42b) * Re(11.30%) + D(688.9m)/V(9.42b) * Rd(3.98%) * (1-Tc(0.13)))
Discount Rate = 11.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 71.59% ; FCFE base≈116.4m ; Y1≈143.6m ; Y5≈245.0m
Fair Price DCF = 44.17 (DCF Value 2.49b / Shares Outstanding 56.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -37.21 | EPS CAGR: -13.25% | SUE: 0.37 | # QB: 0
Revenue Correlation: 18.39 | Revenue CAGR: 0.40% | SUE: 2.59 | # QB: 3

Additional Sources for RGEN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle